Pill achieves results comparable to injectable Wegovy – 05/22/2023 – Health
[ad_1]
Novo Nordisk said Monday that data from a late-stage study showed that an oral version of its weight-loss drug semaglutide helped overweight or obese adults lose an average of 15% to 17% of their weight. your body weight, comparable to your Wegovy injectable medicine.
The Danish drugmaker said in a statement that the main results were statistically significant and showed superior weight loss when compared to a placebo.
The company expects to file an application for regulatory approval in the United States and the European Union in 2023. The global launch of the 50-milligram oral semaglutide drug depends on portfolio priorities and manufacturing capacity, the company added without elaborating.
The phase three study enrolled 667 obese or overweight adults with one or more comorbidities. The treatment was in conjunction with the lifestyle intervention.
Participants who adhered to the treatment experienced an average of 17.4% weight loss after 68 weeks, compared to just 1.8% of those taking the placebo.
Non-compliancers achieved a 15.1% weight loss compared to a 2.4% reduction with placebo.
The results are comparable to the company’s Wegovy injection, said Martin Holst Lange, Novo Nordisk’s head of development, leading to a weight loss of around 15% on average, along with changes in diet and exercise.
“The choice between a daily pill or a weekly injection for obesity has the potential to offer patients and healthcare professionals the opportunity to choose what best fits their individual treatment preferences,” he added.
Novo Nordisk had supply issues and struggled to keep up with rising US demand for Wegovy. The lowest dose of the weekly injection contains only 2.4 mg of semaglutide, while the daily pill contains 50 mg.
A spokesman declined to comment on the pill’s manufacturing capacity, but the company is prioritizing supplying the shot in the United States over launching it in new markets.
Boleslaw Lasocki and Maggie Fick collaborated
[ad_2]
Source link
